Reslizumab for pediatric eosinophilic esophagitis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and their subsequent accumulation, activation and persistence in the tissues. Reslizumab (Cinquil, Ception Therapeutics Inc., PA, USA) is a humanized monoclonal antibody with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. This article considers the current status of the clinical development of reslizumab for pediatric eosinophilic esophagitis.

Original languageEnglish
Pages (from-to)461-465
Number of pages5
JournalImmunotherapy
Volume2
Issue number4
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Eosinophilic Esophagitis
Eosinophils
Interleukin-5
Pediatrics
Antibodies, Monoclonal, Humanized
Esophagus
Gastrointestinal Tract
Mucous Membrane
Bone Marrow
Skin
reslizumab
Therapeutics

Keywords

  • Cinquil (TM)
  • eosinophils
  • IL-5
  • pediatric eosinophilic esophagitis
  • reslizumab
  • IL-5 receptor-alpha
  • human interleukin-5
  • Hypereosinophilic syndrome
  • decreased expression
  • asthma
  • hyperreactivity
  • Mepolizumab
  • antibody
  • gastroenteritis
  • aeroallergens

Cite this

Reslizumab for pediatric eosinophilic esophagitis. / Walsh, Garry Michael.

In: Immunotherapy, Vol. 2, No. 4, 07.2010, p. 461-465.

Research output: Contribution to journalArticle

@article{08515e0737f946f486a38ae9d5d77cea,
title = "Reslizumab for pediatric eosinophilic esophagitis",
abstract = "Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and their subsequent accumulation, activation and persistence in the tissues. Reslizumab (Cinquil, Ception Therapeutics Inc., PA, USA) is a humanized monoclonal antibody with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. This article considers the current status of the clinical development of reslizumab for pediatric eosinophilic esophagitis.",
keywords = "Cinquil (TM), eosinophils, IL-5, pediatric eosinophilic esophagitis, reslizumab, IL-5 receptor-alpha, human interleukin-5, Hypereosinophilic syndrome, decreased expression, asthma, hyperreactivity, Mepolizumab, antibody, gastroenteritis, aeroallergens",
author = "Walsh, {Garry Michael}",
year = "2010",
month = "7",
doi = "10.2217/IMT.10.41",
language = "English",
volume = "2",
pages = "461--465",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Reslizumab for pediatric eosinophilic esophagitis

AU - Walsh, Garry Michael

PY - 2010/7

Y1 - 2010/7

N2 - Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and their subsequent accumulation, activation and persistence in the tissues. Reslizumab (Cinquil, Ception Therapeutics Inc., PA, USA) is a humanized monoclonal antibody with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. This article considers the current status of the clinical development of reslizumab for pediatric eosinophilic esophagitis.

AB - Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and their subsequent accumulation, activation and persistence in the tissues. Reslizumab (Cinquil, Ception Therapeutics Inc., PA, USA) is a humanized monoclonal antibody with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. This article considers the current status of the clinical development of reslizumab for pediatric eosinophilic esophagitis.

KW - Cinquil (TM)

KW - eosinophils

KW - IL-5

KW - pediatric eosinophilic esophagitis

KW - reslizumab

KW - IL-5 receptor-alpha

KW - human interleukin-5

KW - Hypereosinophilic syndrome

KW - decreased expression

KW - asthma

KW - hyperreactivity

KW - Mepolizumab

KW - antibody

KW - gastroenteritis

KW - aeroallergens

U2 - 10.2217/IMT.10.41

DO - 10.2217/IMT.10.41

M3 - Article

VL - 2

SP - 461

EP - 465

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 4

ER -